Complete Filing Data
LianBio reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of -$98.07 million for FY2020.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean LianBio did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Net Income Loss | -$110.3M | -$196.3M | -$139.6M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$1.7M | $512.0K | -$40.0K |
| Research And Development Expense | $59.8M | $158.7M | $120.9M |
| Other Nonoperating Income Expense | $10.4M | -$455.0K | $123.0K |
| Other Comprehensive Income Loss Net Of Tax | -$2.6M | $566.0K | -$40.0K |
| Operating Income Loss | -$125.4M | -$195.6M | -$134.9M |
| Operating Expenses | $125.4M | $195.6M | $134.9M |
| Interest Income Expense Net | $4.3M | $243.0K | -$4.9M |
| Income Tax Expense Benefit | -$333.0K | $518.0K | $4.0K |
| General And Administrative Expense | $65.6M | $36.9M | $14.0M |
| Comprehensive Income Net Of Tax | -$112.9M | -$195.7M | -$139.6M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$894.0K | $54.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$24.0M | -$21.6M | -$24.0M | -$21.9M | -$42.4M | -$27.7M | -$13.1M | -$100.4M | -$61.6M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$130.0K | -$1.6M | $104.0K | -$2.3M | -$421.0K | -$393.0K | -$26.0K | $122.0K | $8.0K |
| Research And Development Expense | $9.0M | $9.5M | $10.8M | $8.3M | $28.6M | $12.3M | $4.7M | $93.0M | $53.4M |
| Other Nonoperating Income Expense | $141.0K | $869.0K | -$44.0K | $1.3M | $203.0K | $417.0K | $3.0K | -$68.0K | -$124.0K |
| Other Comprehensive Income Loss Net Of Tax | $106.0K | -$1.8M | $549.0K | -$2.4M | -$712.0K | -$1.2M | -$26.0K | $122.0K | $8.0K |
| Operating Income Loss | -$26.3M | -$25.0M | -$26.0M | -$24.5M | -$43.1M | -$28.4M | -$13.5M | -$99.5M | -$60.5M |
| Operating Expenses | $26.3M | $25.0M | $26.0M | $24.5M | $43.1M | $28.4M | $13.5M | $99.5M | $60.5M |
| Interest Income Expense Net | $2.7M | $2.8M | $2.4M | $1.4M | $553.0K | $280.0K | $32.0K | $106.0K | $33.0K |
| Income Tax Expense Benefit | $586.0K | $200.0K | $438.0K | $6.0K | $5.0K | $6.0K | -$397.0K | $975.0K | $975.0K |
| General And Administrative Expense | $17.3M | $15.6M | $15.1M | $16.3M | $14.6M | $16.1M | $8.9M | $6.5M | $7.1M |
| Comprehensive Income Net Of Tax | -$23.9M | -$23.4M | -$23.5M | -$24.3M | -$43.1M | -$28.9M | -$13.1M | -$100.3M | -$61.6M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $236.0K | -$154.0K | $445.0K | -$160.0K | -$291.0K | -$823.0K | $0.00 | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Stockholders Equity * | $353.6M | -$132.8M | -$14.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $254.4M | $43.3M | ||
| Restricted Cash Noncurrent | $20.0M | $0.00 | ||
| Cash And Cash Equivalents At Carrying Value | $228.2M | $254.4M | ||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | $0.00 | $0.00 | $349.8M | $55.0M |
| Retained Earnings Accumulated Deficit | -$360.2M | -$163.9M | ||
| Property Plant And Equipment Net | $1.9M | $822.0K | ||
| Prepaid Expense And Other Assets Current | $10.4M | $2.4M | ||
| Other Liabilities Current | $760.0K | $360.0K | ||
| Other Assets Noncurrent | $51.0K | $12.0K | ||
| Operating Lease Right Of Use Asset | $4.8M | $1.7M | ||
| Operating Lease Liability Noncurrent | $3.7M | $1.3M | ||
| Operating Lease Liability Current | $1.1M | $539.0K | ||
| Minority Interest | $33.8M | $34.8M | ||
| Liabilities Current | $15.1M | $6.2M | ||
| Liabilities And Stockholders Equity | $426.3M | $279.3M | ||
| Liabilities | $39.0M | $27.6M | ||
| Common Stock Value | $2.0K | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$168.9M | -$6.2M | $211.1M | |
| Assets Current | $399.6M | $276.7M | ||
| Assets | $426.3M | $279.3M | ||
| Additional Paid In Capital Common Stock | $713.3M | $31.1M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $526.0K | -$40.0K | ||
| Accrued Liabilities Current | $10.0M | $998.0K | ||
| Accounts Payable Current | $3.2M | $4.3M | ||
| Other Receivables Net Current | $6.0M | $20.0M | ||
| Other Liabilities Noncurrent | $206.0K | $0.00 | ||
| Non Cash Operating Lease Expense Benefit | $303.0K | -$106.0K | $169.0K | |
| Marketable Securities Current | $155.1M | $0.00 | ||
| Accretion Amortization Of Discounts And Premiums Investments | $1.6M | $23.0K | $0.00 | |
| Deferred Offering Costs Incurred But Not Yet Paid | $0.00 | $1.5M | $1.2M | |
| Non Cash Share Consideration Issued In Acquisition Of IPR And D | $0.00 | $9.4M | $33.8M | |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $1.1M | $5.2M | $1.4M | |
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | $9.4M | $33.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $202.3M | $221.7M | $240.7M | $259.9M | $272.8M | $292.4M | $331.0M | $387.3M | -$253.1M | -$247.4M | -$148.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $103.5M | $104.1M | $102.4M | $79.3M | $98.9M | $154.4M | $159.9M | $248.2M | $129.0M | $162.6M | $255.3M |
| Restricted Cash Noncurrent | $69.0K | $69.0K | $73.0K | $73.0K | $20.1M | $20.1M | $20.0M | $20.0M | $20.0M | $20.0M | |
| Cash And Cash Equivalents At Carrying Value | $103.5M | $104.1M | $102.3M | $79.2M | $78.9M | $134.3M | $139.9M | $109.0M | $142.6M | $235.3M | |
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | $0.00 | $0.00 | $0.00 | $352.7M | $352.7M | $352.7M | |||||
| Retained Earnings Accumulated Deficit | -$540.2M | -$516.2M | -$494.6M | -$470.5M | -$452.2M | -$430.4M | -$388.0M | ||||
| Property Plant And Equipment Net | $2.4M | $2.6M | $2.8M | $3.1M | $3.1M | $3.0M | $2.9M | ||||
| Prepaid Expense And Other Assets Current | $4.7M | $4.8M | $8.5M | $8.6M | $5.1M | $7.1M | $9.0M | ||||
| Other Liabilities Current | $1.6M | $996.0K | $2.0M | $485.0K | $387.0K | $738.0K | $979.0K | ||||
| Other Assets Noncurrent | $20.0K | $20.0K | $20.0K | $20.0K | $37.0K | $39.0K | $50.0K | ||||
| Operating Lease Right Of Use Asset | $2.6M | $3.0M | $3.6M | $4.0M | $4.4M | $5.0M | $4.4M | ||||
| Operating Lease Liability Noncurrent | $950.0K | $1.4M | $2.0M | $2.5M | $3.0M | $3.7M | $3.3M | ||||
| Operating Lease Liability Current | $1.9M | $1.9M | $1.9M | $1.9M | $1.8M | $1.8M | $1.4M | ||||
| Minority Interest | $33.8M | $33.8M | $33.8M | $33.8M | $33.8M | $33.8M | $33.8M | ||||
| Liabilities Current | $25.6M | $21.6M | $25.9M | $23.6M | $22.0M | $21.7M | $25.2M | ||||
| Liabilities And Stockholders Equity | $262.9M | $278.8M | $302.6M | $320.0M | $351.8M | $371.8M | $413.5M | ||||
| Liabilities | $26.8M | $23.3M | $28.2M | $26.3M | $45.2M | $45.6M | $48.7M | ||||
| Common Stock Value | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $23.1M | -$88.3M | $918.0K | ||||||||
| Assets Current | $257.8M | $273.1M | $296.1M | $312.8M | $324.2M | $343.7M | $386.1M | ||||
| Assets | $262.9M | $278.8M | $302.6M | $320.0M | $351.8M | $371.8M | $413.5M | ||||
| Additional Paid In Capital Common Stock | $745.8M | $741.2M | $736.8M | $732.5M | $728.9M | $724.2M | $719.6M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$3.2M | -$3.3M | -$1.5M | -$2.1M | -$3.8M | -$1.4M | -$690.0K | ||||
| Accrued Liabilities Current | $15.9M | $16.9M | $16.6M | $19.8M | $17.9M | $18.0M | $14.9M | ||||
| Accounts Payable Current | $6.2M | $1.9M | $5.4M | $1.5M | $2.0M | $1.2M | $7.9M | ||||
| Other Receivables Net Current | $910.0K | $1.0M | $1.0M | $1.8M | $7.4M | $7.3M | $6.0M | ||||
| Other Liabilities Noncurrent | $213.0K | $210.0K | $217.0K | $210.0K | $200.0K | $208.0K | $207.0K | ||||
| Non Cash Operating Lease Expense Benefit | $277.0K | -$20.0K | |||||||||
| Marketable Securities Current | $148.8M | $163.2M | $184.2M | $223.1M | $232.9M | $195.0M | $229.3M | ||||
| Accretion Amortization Of Discounts And Premiums Investments | $1.2M | $44.0K | $0.00 | ||||||||
| Deferred Offering Costs Incurred But Not Yet Paid | $0.00 | $630.0K | $314.0K | ||||||||
| Non Cash Share Consideration Issued In Acquisition Of IPR And D | $0.00 | $9.4M | |||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||||||||
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | $9.4M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Share Based Compensation | $19.1M | $8.7M | $5.2M |
| Payments To Acquire Property Plant And Equipment | $1.8M | $947.0K | $886.0K |
| Net Cash Provided By Used In Operating Activities | -$99.2M | -$164.0M | -$98.1M |
| Net Cash Provided By Used In Investing Activities | -$69.2M | -$155.9M | -$886.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.3M | $8.2M | $2.3M |
| Increase Decrease In Other Receivables | $1.4M | -$14.2M | $20.0M |
| Increase Decrease In Other Current Liabilities | -$97.0K | $732.0K | $375.0K |
| Increase Decrease In Accrued Liabilities | $9.8M | $8.8M | $811.0K |
| Increase Decrease In Accounts Payable | -$1.7M | -$1.7M | $4.2M |
| Payments To Acquire Marketable Securities | $303.1M | $155.0M | $0.00 |
| Net Cash Provided By Used In Financing Activities | $1.7M | $313.3M | $309.8M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$2.2M | $449.0K | $325.0K |
| Proceeds From Stock Options Exercised | $1.7M | $5.5M | $0.00 |
| Proceeds From Sale And Maturity Of Marketable Securities | $235.8M | $0.00 | |
| Increase Decrease In Other Noncurrent Assets | -$27.0K | $40.0K | $7.0K |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $0.00 | $3.0M | $310.0M |
| Payments Of Stock Issuance Costs |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Share Based Compensation | $4.3M | $4.7M | $1.7M |
| Payments To Acquire Property Plant And Equipment | $19.0K | $344.0K | $29.0K |
| Net Cash Provided By Used In Operating Activities | -$17.6M | -$13.1M | -$1.9M |
| Net Cash Provided By Used In Investing Activities | $40.5M | -$75.3M | -$29.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$159.0K | -$1.5M | -$173.0K |
| Increase Decrease In Other Receivables | -$757.0K | $0.00 | -$20.0M |
| Increase Decrease In Other Current Liabilities | $1.5M | $116.0K | $929.0K |
| Increase Decrease In Accrued Liabilities | -$3.3M | $4.7M | $28.7M |
| Increase Decrease In Accounts Payable | $4.0M | $3.8M | -$1.2M |
| Payments To Acquire Marketable Securities | $45.8M | $93.4M | $0.00 |
| Net Cash Provided By Used In Financing Activities | $0.00 | $2.9M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $201.0K | $109.0K | -$82.0K |
| Proceeds From Stock Options Exercised | |||
| Proceeds From Sale And Maturity Of Marketable Securities | $86.4M | $18.4M | $0.00 |
| Increase Decrease In Other Noncurrent Assets | |||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $0.00 | $3.0M | |
| Payments Of Stock Issuance Costs | $0.00 | $60.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 11.0M | 5.5M |
| Weighted Average Number Of Shares Outstanding Basic | 107.9M | 34.4M | 12.1M | |
| Weighted Average Number Of Diluted Shares Outstanding | 107.9M | 34.4M | 12.1M | |
| Earnings Per Share Diluted | $-1.02 | $-5.71 | $-11.58 | |
| Earnings Per Share Basic | $-1.02 | $-5.71 | $-11.58 | |
| Common Stock Shares Outstanding | 107.3M | 20.5M | ||
| Common Stock Shares Issued | 107.3M | 20.5M | ||
| Common Stock Shares Authorized | 2.92B | 2.86B | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 0.00 | 11.0M | 11.0M | 11.0M | ||||
| Weighted Average Number Of Shares Outstanding Basic | 107.2M | 107.2M | 107.2M | 108.4M | 107.9M | 107.3M | 20.7M | 20.5M | 20.5M | |
| Weighted Average Number Of Diluted Shares Outstanding | 107.2M | 107.2M | 107.2M | 108.4M | 107.9M | 107.3M | 20.7M | 20.5M | 20.5M | |
| Earnings Per Share Diluted | $-0.22 | $-0.20 | $-0.22 | $-0.20 | $-0.39 | $-0.26 | $-0.63 | $-4.90 | $-3.01 | |
| Earnings Per Share Basic | $-0.22 | $-0.20 | $-0.22 | $-0.20 | $-0.39 | $-0.26 | $-0.63 | $-4.90 | $-3.01 | |
| Common Stock Shares Outstanding | 107.2M | 107.2M | 107.2M | 107.0M | 108.4M | 108.4M | 107.3M | |||
| Common Stock Shares Issued | 107.2M | 107.2M | 107.2M | 107.0M | 108.4M | 108.4M | 107.3M | |||
| Common Stock Shares Authorized | 2.92B | 2.92B | 2.92B | 2.92B | 2.92B | 2.92B | 2.92B | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $19.1M | $8.7M | $5.2M |
| Income Loss Attributable To Parent | -$110.6M | -$195.8M | -$139.6M |
| Depreciation | $1.0M | $525.0K | $76.0K |
| Foreign Currency Transaction Gain Loss Unrealized | -$127.0K | -$87.0K | $380.0K |
| Capital Expenditures Incurred But Not Yet Paid | $551.0K | $613.0K | $0.00 |
| Nonrefundable Research Deposit | $0.00 | $20.0M | $20.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.5M | $4.5M | $4.3M | $4.7M | $4.5M | $4.7M | $2.2M | $1.4M | $1.7M |
| Income Loss Attributable To Parent | -$23.5M | -$21.4M | -$23.6M | -$21.9M | -$42.4M | -$27.7M | -$13.5M | -$99.5M | -$60.6M |
| Depreciation | $300.0K | $300.0K | $324.0K | $200.0K | $200.0K | $271.0K | $100.0K | $100.0K | $66.0K |
| Foreign Currency Transaction Gain Loss Unrealized | $66.0K | $294.0K | $66.0K | ||||||
| Capital Expenditures Incurred But Not Yet Paid | $12.0K | $963.0K | $0.00 | ||||||
| Nonrefundable Research Deposit | $20.0M | $20.0M | $20.0M |
Most recent annual filing with the SEC: March 28, 2023
Data sourced from SEC EDGAR public filings as of August 6, 2026.